Bullous Pemphigoid Develops Independently of DAP12
Biomolecules · 2025
DOI: 10.3390/biom15111549 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2025. Verfasst von Manuela Pigors und 10 weiteren Autor:innen. Beteiligte Einrichtung: Lübeck Institute of Experimental Dermatology, University of Lübeck, 23562 Lübeck, Germany. Hauptthemen laut MEDLINE: Pemphigoid, Bullous, Adaptor Proteins, Signal Transducing, Membrane Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, University of Lübeck, Incyte (United States).
Abstract (Originalsprache)
The adaptor molecule DNAX-activating protein of 12 kDa (DAP12) is broadly expressed in innate immune cells, but its role in autoimmunity remains unclear due to its dual regulatory functions. We investigated the contribution of the DAP12 pathway to bullous pemphigoid (BP), the most common autoimmune blistering disease, using a mouse model induced by transfer of anti-type XVII collagen (Col17) IgG. Repeated anti-Col17 IgG injections over 12 days produced comparable disease activity in DAP12-deficient and wildtype mice (n = 17/group), indicating that disease induction occurs independently of DAP12 signaling. Flow cytometry and immunofluorescence analysis of lesional skin further revealed a strong upregulation of the DAP12-associated triggering receptors expressed on myeloid cells (TREM) 1 in wildtype BP lesions, whereas TREM2+ cell frequencies in anti-Col17 IgG-treated wildtype and DAP12 knock-out animals were significantly lower than in healthy controls. Additional flow cytometry analysis demonstrated altered inflammatory infiltrates with notably reduced frequencies of Siglec-f+ eosinophils in DAP12-deficient vs. wildtype lesional skin. In addition, pharmacological inhibition of PI3Kδ, a downstream kinase of the DAP12/TREM pathway, did not affect disease progression in anti-Col17 IgG-induced BP. Collectively, these findings indicate that while DAP12 signaling modulates local immune cell composition, the DAP12/TREM1/2-axis does not influence overall disease activity in experimental BP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lübeck Institute of Experimental Dermatology, University of Lübeck, 23562 Lübeck, Germany.
- Incyte Research Institute, Wilmington, DE 19803, USA.
- Department of Dermatology, Allergology and Venerology, University of Lübeck, 23538 Lübeck, Germany.
ORCID-Profile: Manuela Pigors, Sabrina Patzelt, Shirin Emtenani, Katja Bieber
Förderung
- Deutsche Forschungsgemeinschaft
- University of Lübeck
- Incyte (United States)
- German Research Foundation
- Incyte Corporation
Zitieren
APA
Pigors, M., Patzelt, S., Brudey, M., Emtenani, S., Khil'chenko, S., Kamaguchi, M., Reichhelm, N., Parker, M., Bieber, K., Ludwig, R. J., & Schmidt, E. (2025). Bullous Pemphigoid Develops Independently of DAP12. Biomolecules. https://doi.org/10.3390/biom15111549
Vancouver
Pigors M, Patzelt S, Brudey M, Emtenani S, Khil'chenko S, Kamaguchi M, et al. Bullous Pemphigoid Develops Independently of DAP12. Biomolecules. 2025. doi:10.3390/biom15111549
BibTeX
@article{Pigors2025,
author = {Pigors, Manuela and Patzelt, Sabrina and Brudey, Maëlys and Emtenani, Shirin and Khil'chenko, Stanislav and Kamaguchi, Mayumi and Reichhelm, Niklas and Parker, Melissa and Bieber, Katja and Ludwig, Ralf J and Schmidt, Enno},
title = {Bullous Pemphigoid Develops Independently of DAP12},
journal = {Biomolecules},
year = {2025},
doi = {10.3390/biom15111549}
}
EUVIMED